Przemysł leków odtwórczych - globalizacja i konsolidacja

• Autorzy: Katarzyna Nędzi

Warianty tytułu

Generic Drugs Industry - Globalization and Consolidation

• Języki publikacji: PL

Abstrakty

EN

Intense competition, pressure to reduce prices, lower margins, increasing costs and regulatory demands have contributed to surges in mergers and acquisitions (M&A) in the generic pharmaceutical industry. The situation of innovative firms is similar. As pressure continues to mount, it seems likely that integration of the pharmaceutical sector will continue. CEOs have always seen M&A as a tool to create corporate growth and development.The article presents the necessity for generic firms to change the strategy and the traditional business model in order to maintain their share of the market. Successful companies will be these that recognize the need for change earlier than their competition and respond with activities towards gaining competitive advantage. The future for small local generic firms is uncertain. Even given the high growth rates of sales, decreasing margins will reduce their profits. Progressing consolidation among the manufacturers of active pharmaceutical ingredients (API) may be a threat to small scattered generic firms, limiting their access to strategic materials. The solution that strengthens the level of competitiveness of firms may be vertical consolidation with API manufacturers.The influence of the factors presented in this paper, slowly makes backward integration into API production indispensable for companies to grow and gain competitive advantage on the generic market.(original abstract)

Słowa kluczowe

PL

Leki; Przemysł farmaceutyczny; Konsolidacja; Globalizacja

EN

Medications; Pharmaceutical industry; Consolidation; Globalization

• Czasopismo: Problemy Zarządzania
• Rocznik: 2006
• Tom: 4
• Numer: nr 2(12) Zarządzanie i marketing
• Strony: 92--105

Twórcy

autor

Katarzyna Nędzi

• Uniwersytet Warszawski

Bibliografia

• Class, S. 2005. Whither generics? Why major restructuring lies ahead. Journal of Generic Medicines, vol. 2, nr 3, s. 232-239.
• Cloud, F. 2005. Novartis/Hexal -Lessons for the generics industry. Journal of Generic Medicines, vol. 2, nr 4, s. 347-349.
• Coles, S. 2002. Perspectives Focus: Pharma M&A-Survival of the Fattest? w: Perspectives on Ufe Sciences, Londyn: Cap Gemini Ernst & Young.
• Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products, OJ L 182 of 2.7.1992, p. 1.
• Directive 2001/83/EC of the European Parliament and of the Council of 6 November on the Community code relating to medicinal products for human use, as amended by Directive 2002/98/EC, Directive 2004/24/EC, Directive 2004/27/EC, OJ L 311 of 28.11.2004, p. 67-128.
• Erdei, T. 2004. M&A strategy within the generic pharmaceuticals sector: Vertical integration into active pharmaceutical ingredients. Journal of Generic Medicines, vol. 2, nr 1, s. 18-22.
• Hannaford, S. 2003. Industry brief: Pharmaceuticals, http://www.oligopolywatch.com/2003/05/25.html.
• Hoffman, J. 2004. Global generics profitability: Increasing need for business developement and licesing. Journal of Generic Medicines, vol. 2, nr 1, s. 9-17.
• Mazurek, A. i J. Spławiński. 2001. Apteka skarbów. Wprost, nr 13, s. 90-91.
• Skiba A. 2006. Personalne roszady zamiast decyzji. Gazeta Prawna, nr 4, s. 6.
• Sommerfeld, T. 2005. Strategie options for mid-sized generic players. Journal of Generic Medicines, vol. 2, nr 4, s. 308-315.
• Turner, N. 2004. Generics: moving up the value chain to higher priced products,http://pharmalicensing.com/features/disp/1087390506_40d0432b01a0c.
• ---